Heart Transplant
📧 Sign up to get email alerts when something new happens for Heart Transplant.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Results: Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score [Phase 3]
Phase 3 trial comparing tacrolimus/everolimus versus tacrolimus/mycophenolate in pediatric heart transplant recipients using the MATE score;…
-
CLINICAL_TRIALS other · 2026-04-08Clinical Trial Update: Effects of Physical Training in Patients With Advanced Heart Failure [NA]
Clinical trial investigating the effects of physical training in patients with advanced heart failure; recruitment has not yet begun.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP) [NA]
Clinical trial update indicates the XVIVO Heart Box with supplemented XVIVO Heart Solution continued access protocol is currently recruiting…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Cardiopulmonary Stress Testing (CPET) AlloSure Study
Clinical trial update for the Cardiopulmonary Stress Testing (CPET) AlloSure Study sponsored by Baylor Research Institute; the study is curr…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation [NA]
MCNAIR compares in-person versus telehealth cardiac rehabilitation and is currently recruiting for multiple cardiovascular conditions includ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: Exercise aNd hEArt Transplant [NA]
Clinical trial update indicating an exercise program for heart transplant recipients is currently recruiting.
-
FDA approval · 2025-07-15FDA Approved: SIROLIMUS — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings, Inc.'s original application for sirolimus, a generic immunosuppressant used to prevent organ transp…
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: Heart EXPAND Continued Access Protocol [NA]
Update on TransMedics' Heart EXPAND continued access protocol for heart transplant patients; the study status is completed and results were …
-
CLINICAL_TRIALS trial_result · 2024-11-01Clinical Trial Update: A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time [Phase 2]
This Phase 2 pediatric trial compares tacrolimus formulations Advagraf and Prograf in heart, kidney, and liver transplant recipients to asse…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
A completed clinical trial from sponsor Natera is evaluating non-invasive cell-free DNA testing to replace invasive biopsies in heart transp…
-
FDA approval · 2024-09-26FDA Approved: MYCOPHENOLATE MOFETIL — Original Application (Aurobindo Pharma Limited)
The FDA approved the original application for mycophenolate mofetil from Aurobindo Pharma Limited, granting generic approval for use in tran…
-
FDA approval · 2024-09-20FDA Approved: TACROLIMUS — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for tacrolimus by Mylan Pharmaceuticals Inc., enabling changes to its labeling. This relates to …
-
FDA approval · 2024-05-29FDA Approved: MYCOPHENOLIC ACID — Original Application (Novugen Pharma (USA) LLC.)
FDA approved an original application for mycophenolic acid, enabling a generic version of the immunosuppressant used to prevent organ transp…
-
FDA approval · 2024-04-08FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
FDA approved a supplemental application for ENVARSUS XR (tacrolimus extended-release) submitted by Veloxis Pharmaceuticals, Inc.
-
FDA approval · 2023-09-18FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for Accord Healthcare's generic mycophenolate mofetil, supporting its use to prevent organ trans…
-
FDA approval · 2023-09-14FDA Approved: ENVARSUS XR — Supplemental Application (Veloxis Pharmaceuticals, Inc)
FDA approved a supplemental application for ENVARSUS XR (tacrolimus) from Veloxis Pharmaceuticals, Inc., typically affecting the product's l…
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: Health Coaching to Improve Self-Management in Thoracic Transplant Candidates [NA]
Clinical trial update assessing health coaching to improve self-management in thoracic transplant candidates; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2022-04-13Clinical Trial Update: Renal Tubular Injury and Transplant Outcomes in Cardiac Recipients Converting From IR Tacrolimus to XR Tacrolimus [Phase 4]
Phase 4 clinical trial evaluating renal tubular injury and transplant outcomes when converting from IR tacrolimus to XR tacrolimus in cardia…
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil hydrochloride) submitted by Genentech, authorizing an update to …
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Strides Pharma Science Limited)
FDA approved a supplemental application for Mycophenolate mofetil submitted by Strides Pharma Science Limited. The approval covers the gener…
-
FDA approval · 2021-04-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approves Hikma Pharmaceuticals USA Inc.'s supplemental application for Mycophenolate mofetil, a generic immunosuppressant used to preven…
-
FDA approval · 2021-03-12FDA Approved: SIROLIMUS — Original Application (Ascend Laboratories, LLC)
FDA approves the original (generic) application for sirolimus from Ascend Laboratories, authorizing its marketing as an immunosuppressant. T…
-
FDA approval · 2021-01-15FDA Approved: MYFORTIC — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Myfortic (mycophenolic acid) submitted by Novartis Pharmaceuticals Corporation. The approval typ…
-
FDA approval · 2021-01-15FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for mycophenolate mofetil (generic) submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients [Phase 3]
Phase 3 trial update assessing efficacy and safety of everolimus in de novo heart transplant recipients has completed.